Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 10/20 | 0.62 |
| ▸ | CASP7 | P55210 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.62 |
| ▸ | CBFB | Q13951 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133306 | 0.81 | KDM4E (0.55) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL5014910 | 0.80 | KDM4E (0.72) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL29232119 | 0.74 | RET (0.47) | KMT2AKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL24970930 | 0.73 | TAAR1 (0.57) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL31142938 | 0.73 | TAAR1 (0.57) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL12043094 | 0.73 | KDM4E (0.85) | CASP1CASP7MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL29268332 | 0.72 | TAAR1 (0.56) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL2525573 | 0.72 | KDM4E (0.84) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL1445522 | 0.72 | KDM4E (0.69) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL16940596 | 0.72 | KDM4E (0.62) | CASP1CASP7MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937252-B1 | COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9539261-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8999972-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20110319391-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT, INC. | 2011-12-29 | — | — | US | disclosed |
| US-8039462-B2 | Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells | NEURONASCENT, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1937252-A2 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | Neuronascent, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007035722-A2 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319391-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | DCX, BDNF, GAP43 | CASP1 1470/4885CASP7 905/4885MEN1 2489/4885 |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | DCX, BDNF, GAP43 | CASP1 571/4885CASP7 497/4885MEN1 1487/4885 |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | DCX, BDNF, GAP43 | CASP1 1470/4885CASP7 905/4885MEN1 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.